POLB vs. FUM, MPH, SCLP, ORPH, REDX, ETX, TRX, SBTX, COS, and C4XD
Should you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Futura Medical (FUM), Mereo BioPharma Group plc (MPH.L) (MPH), Scancell (SCLP), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), and C4X Discovery (C4XD). These companies are all part of the "biotechnology" industry.
Poolbeg Pharma vs.
Futura Medical (LON:FUM) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends.
Futura Medical received 186 more outperform votes than Poolbeg Pharma when rated by MarketBeat users. Likewise, 64.36% of users gave Futura Medical an outperform vote while only 0.00% of users gave Poolbeg Pharma an outperform vote.
35.7% of Futura Medical shares are owned by institutional investors. Comparatively, 1.2% of Poolbeg Pharma shares are owned by institutional investors. 32.1% of Futura Medical shares are owned by insiders. Comparatively, 24.7% of Poolbeg Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Poolbeg Pharma has a net margin of 0.00% compared to Futura Medical's net margin of -44.68%. Poolbeg Pharma's return on equity of -30.18% beat Futura Medical's return on equity.
In the previous week, Futura Medical had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 1 mentions for Futura Medical and 0 mentions for Poolbeg Pharma. Futura Medical's average media sentiment score of 0.59 beat Poolbeg Pharma's score of 0.00 indicating that Futura Medical is being referred to more favorably in the media.
Futura Medical has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Poolbeg Pharma has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500.
Futura Medical has higher revenue and earnings than Poolbeg Pharma. Futura Medical is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Futura Medical beats Poolbeg Pharma on 8 of the 13 factors compared between the two stocks.
Get Poolbeg Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poolbeg Pharma Competitors List
Related Companies and Tools
This page (LON:POLB) was last updated on 1/21/2025 by MarketBeat.com Staff
